These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37175923)

  • 1. Novel Knowledge about Molecular Mechanisms of Heparin-Induced Thrombocytopenia Type II and Treatment Targets.
    Mongirdienė A; Liuizė A; Kašauskas A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.
    Greinacher A; Warkentin TE
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):1-10. PubMed ID: 38066843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
    Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
    J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.
    Kasthuri RS; Glover SL; Jonas W; McEachron T; Pawlinski R; Arepally GM; Key NS; Mackman N
    Blood; 2012 May; 119(22):5285-93. PubMed ID: 22394597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?
    Campello E; Radu CM; Duner E; Lombardi AM; Spiezia L; Bendo R; Ferrari S; Simioni P; Fabris F
    Cytometry B Clin Cytom; 2018 Mar; 94(2):334-341. PubMed ID: 28052584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.
    Tutwiler V; Madeeva D; Ahn HS; Andrianova I; Hayes V; Zheng XL; Cines DB; McKenzie SE; Poncz M; Rauova L
    Blood; 2016 Jan; 127(4):464-72. PubMed ID: 26518435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of heparin-induced thrombocytopenia.
    Warkentin TE; Greinacher A
    Curr Opin Hematol; 2016 Sep; 23(5):462-70. PubMed ID: 27380556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia.
    McKenzie SE; Sachais BS
    Curr Opin Hematol; 2014 Sep; 21(5):380-7. PubMed ID: 24992313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.
    Kizlik-Masson C; Deveuve Q; Zhou Y; Vayne C; Thibault G; McKenzie SE; Pouplard C; Loyau S; Gruel Y; Rollin J
    Blood; 2019 May; 133(22):2427-2435. PubMed ID: 30917957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia.
    Perdomo J; Leung HHL; Ahmadi Z; Yan F; Chong JJH; Passam FH; Chong BH
    Nat Commun; 2019 Mar; 10(1):1322. PubMed ID: 30899022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
    Warkentin TE
    Thromb Res; 2003 May; 110(2-3):73-82. PubMed ID: 12893020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
    Krauel K; Hackbarth C; Fürll B; Greinacher A
    Blood; 2012 Feb; 119(5):1248-55. PubMed ID: 22049520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the heparin-induced thrombocytopenia syndrome.
    Warkentin TE
    Semin Thromb Hemost; 2004 Jun; 30(3):273-83. PubMed ID: 15282649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.
    Lee CSM; Selvadurai MV; Pasalic L; Yeung J; Konda M; Kershaw GW; Favaloro EJ; Chen VM
    J Thromb Haemost; 2022 Apr; 20(4):975-988. PubMed ID: 35038779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of heparin-induced thrombocytopenia and thrombosis.
    Arepally G; Cines DB
    Autoimmun Rev; 2002 May; 1(3):125-32. PubMed ID: 12849005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of monocytes and endothelial cells in heparin-induced thrombocytopenia.
    Madeeva D; Cines DB; Poncz M; Rauova L
    Thromb Haemost; 2016 Oct; 116(5):806-812. PubMed ID: 27487857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects.
    Castelli R; Cassinerio E; Cappellini MD; Porro F; Graziadei G; Fabris F
    Cardiovasc Hematol Disord Drug Targets; 2007 Sep; 7(3):153-62. PubMed ID: 17896955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors.
    Rollin J; Pouplard C; Gruel Y
    Thromb Haemost; 2016 Oct; 116(5):799-805. PubMed ID: 27358188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia: a ten-year retrospective.
    Warkentin TE
    Annu Rev Med; 1999; 50():129-47. PubMed ID: 10073268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.